Results 1 to 10 of about 32,000 (119)

BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study [PDF]

Frontiers in Oncology
ObjectiveOlaparib is a standard maintenance therapy for epithelial ovarian cancer, particularly in patients with BRCA mutations. While BRCA status is an established predictive biomarker for efficacy, its potential impact on treatment-related toxicity ...
Yuewen Gao, Yuewen Gao, Minxue Gai, Hongyang Zhang, Hongqi Li   +4 more
doaj   +2 more sources

Fertility preservation in BRCA mutation carriers—efficacy and safety issues: a review

Reproductive Biology and Endocrinology, 2020
BRCA mutation carriers face various situations that influence their fertility potential. There is still a lack of guideline or expert consensus on Fertility Preservation (FP) in BRCA mutation carriers and the necessity and safety of FP in BRCA mutation ...
Xiaofu Zhang, Jingxin Niu, Tuanjie Che, Yibei Zhu, Hongtao Zhang, Jing Qu   +5 more
doaj   +1 more source

HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. [PDF]

PLoS ONE, 2013
Recent studies have revealed that BRCA1 and BRCA2 germline mutation-related breast cancers show frequent overexpression of hypoxia inducible factor-1α (HIF-1α), the key regulator of the hypoxia response.
Petra van der Groep, Paul J van Diest, Yvonne H C M Smolders, Margreet G E M Ausems, Rob B van der Luijt, Fred H Menko, Joost Bart, Elisabeth G E de Vries, Elsken van der Wall   +8 more
doaj   +1 more source

Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic

Gynecologic Oncology Reports, 2020
Recent data suggest that BRCA mutation carriers younger than 40 may not benefit from mammography in addition to MRI. Our objective was to evaluate screening modalities utilized in a high-risk population.
Anne T. Knisely, Martha E. Stewart, Christine Garcia, Martha H. Thomas, Susan C. Modesitt, Kari L. Ring   +5 more
doaj   +1 more source

Development of a novel BRCAness score that predicts response to PARP inhibitors

Biomarker Research, 2022
Background BRCAness is a characteristic feature of homologous recombination deficiency (HRD) mimicking BRCA gene mutation in breast cancer. We hypothesized that a measure to quantify BRCAness that causes synthetic lethality in BRCA mutated tumors will ...
Masanori Oshi, Shipra Gandhi, Rongrong Wu, Mariko Asaoka, Li Yan, Akimitsu Yamada, Shinya Yamamoto, Kazutaka Narui, Takashi Chishima, Takashi Ishikawa, Itaru Endo, Kazuaki Takabe   +11 more
doaj   +1 more source

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy [PDF]

Journal of Pathology and Translational Medicine, 2023
Background Homologous recombination defect is an important biomarker of chemotherapy in certain tumor types, and the presence of pathogenic or likely pathogenic mutations involving BRCA1 or BRCA2 (p-BRCA) mutations is the most well-established marker for
Ji Hyun Oh, Chang Ohk Sung, Hyung-Don Kim, Sung-Min Chun, Jihun Kim   +4 more
doaj   +1 more source

Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients

Frontiers in Endocrinology, 2019
Background: Several preclinical and clinical studies have suggested that BRCA-mutation carriers may have decreased ovarian reserve. However, data in this area are limited and inconsistent, especially in young breast cancer patients.Objective: This study ...
Kyung-A Son, Dong-Yun Lee, DooSeok Choi
doaj   +1 more source

Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing [PDF]

PeerJ, 2013
Background. Inherited BRCA gene mutations convey a high risk for breast and ovarian cancer, but current guidelines limit BRCA mutation testing to women with early-onset cancer and relatives of mutation-positive cases. Benefits and risks of providing this
Uta Francke, Cheri Dijamco, Amy K. Kiefer, Nicholas Eriksson, Bianca Moiseff, Joyce Y. Tung, Joanna L. Mountain   +6 more
doaj   +2 more sources

Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis

Reproductive Biology and Endocrinology, 2021
Background Gynecologic oncologists should be aware of the option of conception through IVF/PGT-M for families with high BRCA related morbidity or mortality.
Nadav Michaan, Moshe Leshno, Yoni Cohen, Tamar Safra, Shira Peleg-Hasson, Ido Laskov, Dan Grisaru   +6 more
doaj   +1 more source

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer

Frontiers in Oncology, 2021
BackgroundLittle is known regarding the clinicopathologic characteristics, oncologic outcomes, and treatment strategies that could be ascribed to BRCA mutation in early-onset triple-negative breast cancer (eTNBC).MethodseTNBC patients who underwent BRCA ...
Fugui Ye, Min He, Liang Huang, Guantian Lang, Guantian Lang, Xin Hu, Zhimin Shao, Zhimin Shao, Genhong Di, Ayong Cao   +9 more
doaj   +1 more source